切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2020, Vol. 14 ›› Issue (06) : 453 -460. doi: 10.3877/cma.j.issn.1674-1358.2020.06.003

所属专题: 经典病例 文献

论著

2008-2018年某院167例丙型肝炎病毒合并人类免疫缺陷病毒感染者的临床特征及治疗
赵凤丛1, 马合木热·艾则孜2, 努斯来提1, 张永萍1, 成军3,()   
  1. 1. 830001 乌鲁木齐市,新疆维吾尔自治区人民医院感染性疾病科
    2. 830013 乌鲁木齐市,新疆维吾尔自治区第六人民医院感染二科
    3. 100015 北京,首都医科大学附属北京地坛医院肝病中心
  • 收稿日期:2020-02-10 出版日期:2020-12-25
  • 通信作者: 成军
  • 基金资助:
    新发突发传染病研究北京市重点实验室开放课题资助项目(No. DTKF201802)

Clinical features and treatment of 167 patients with hepatitis C virus and human immunodeficiency virus coinfection in a hospital from 2008 to 2018

Fengcong Zhao1, Aizezi Mahemure2, Nusilaiti1, Yongping Zhang1, Jun Cheng3,()   

  1. 1. Department of Infectious Diseases, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China
    2. Division of 2nd Department of Infectious Diseases, the Sixth People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830013, China
    3. Center of Hepatology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
  • Received:2020-02-10 Published:2020-12-25
  • Corresponding author: Jun Cheng
引用本文:

赵凤丛, 马合木热·艾则孜, 努斯来提, 张永萍, 成军. 2008-2018年某院167例丙型肝炎病毒合并人类免疫缺陷病毒感染者的临床特征及治疗[J/OL]. 中华实验和临床感染病杂志(电子版), 2020, 14(06): 453-460.

Fengcong Zhao, Aizezi Mahemure, Nusilaiti, Yongping Zhang, Jun Cheng. Clinical features and treatment of 167 patients with hepatitis C virus and human immunodeficiency virus coinfection in a hospital from 2008 to 2018[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2020, 14(06): 453-460.

目的

探讨丙型肝炎病毒(HCV)合并人类免疫缺陷病毒(HIV)感染者的临床特征及治疗现状,为HIV/HCV共感染的治疗提供科学指导。

方法

基于医院信息系统真实世界数据,提取2008年5月至2018年5月新疆维吾尔自治区第六人民医院(传染病医院)和新疆维吾尔自治区人民医院收治的167例HIV/AIDS患者的病历资料。依据医嘱记录,对HIV/HCV共感染者按照抗HCV方案分为聚乙二醇化干扰素α-2b(PegIFNα-2b)联合利巴韦林(RBV)治疗组(PegIFN组、62例),普通干扰素联合RBV治疗组(IFN组、46例)与直接抗病毒药物(DAAs)治疗组(DAAs组、59例);分析3组患者CD4+ T淋巴细胞、丙氨酸氨基转移酶(ALT)和天门冬氨酸氨基转移酶(AST)的变化、病毒学应答及不良反应发生率。

结果

共收集659例HIV/AIDS感染者的临床资料,其中合并HCV感染共计167例,合并感染率为25.34%。HCV基因型别主要为:3b型43例、3a型41例、1b型32例、6a型21例、未分出亚型25例、2a型5例,以3型最多,占50.29%(84/167)。其中经静脉吸毒感染占29.40%(142/483),性传播占14.20%(23/162),其他占14.29%(2/14)。125例患者无明显症状,42例患者出现虚弱、发热、盗汗、肝硬化、淋巴结肿大等症状。肝功能检查发现:肝功能正常者56例(56/167、33.53%),肝功能异常者111例(111/167、66.47%),其中12例为肝硬化代偿期,7例为肝硬化失代偿期。HIV/HCV共感染率自2008年的37.25%下降至2018年的15.00%,且呈逐年下降,趋势卡方检验显示差异有统计学意义(χ2 = 263.190、P < 0.001)。HIV/HCV共感染者CD4+ T细胞计数显著高于单纯HIV/AIDS患者(t = 7.203、P < 0.001),总胆红素(TBil)(t = 29.101、P < 0.001)、ALT(t = 25.382、P < 0.001)、AST(t = 30.984、P < 0.001)、HIV RNA(t = 9.190、P < 0.001)均显著低于单纯HIV/AIDS患者,差异均有统计学意义。各组患者治疗后CD4+ T淋巴细胞数均较治疗前升高,且DAAs组患者高于PegIFN组和IFN组;3组患者治疗后ALT、AST水平均较治疗前降低,且DAAs组患者高于PegIFN组和IFN组,差异具有统计学意义(CD4+ T淋巴细胞数:F = 4.252、P = 0.016;ALT:F = 125.400、P < 0.001;AST:F = 37.990、P < 0.001)。DAAs组患者早期病毒学应答率(EVR)(96.61%)高于PegIFN组(77.42%)和IFN组(71.74%);DAAs组患者治疗结束病毒学应答率(ETVR)(96.61%)高于PegIFN组(72.58%)和IFN组(63.04%);DAAs组患者持续病毒学应答率(SVR)(94.92%)高于PegIFN组(69.35%)和IFN组(67.39%);差异均有统计学意义(EVR:χ2 = 13.011、P = 0.001;ETVR:χ2 = 19.227、P < 0.001;SVR:χ2 = 14.474、P < 0.001)。DAAs组患者乏力、发热、白细胞下降、血红蛋白下降、血小板下降发生率均低于PegIFN组和IFN组,差异均有统计学意义(乏力:χ2 = 6.678、P = 0.035;发热:χ2 = 12.485、P = 0.002;白细胞下降:χ2 = 10.256、P = 0.006;血红蛋白下降:χ2 = 13.962、P = 0.001;血小板下降:χ2 = 11.681、P = 0.003)。

结论

HIV/HCV共感染率较高,以HCV基因3型最为常见,感染率呈逐年下降趋势,主要通过静脉吸毒途径传播。DAAs治疗HIV/HCV共感染更有利于患者免疫功能、肝功能的恢复,获得更高SVR,安全性较高。

Objective

To investigate the clinical characteristics and treatment status of patients with hepatitis C virus (HIV) and human immunodeficiency virus (HIV) infection, and to provide scientific guidance for HIV/HCV co-infection treatment.

Methods

Based on real-world data from hospital information system, medical records of 167 patients with HIV/acquired immune deficiency syndrome (AIDS) from the Sixth People’s Hospital of Xinjiang Uygur Autonomous Region (Infectious Diseases Hospital) and Xinjiang Uygur Autonomous Region People’s Hospital were collected from May 2008 to May 2018. According to medical records, patients with HIV/HCV co-infection were divided into polyethylene glycol interferon-α-2b (PegIFNα-2b) and ribavirin (RBV) treatment group (PegIFN group: 62 cases), common IFN and RBV treatment group (IFN group: 46 cases) and direct acting antivirals (DAAs) treatment group (DAAs group: 59 cases). The changes of CD4+ T lymphocytes, alanine transaminase (ALT), aspartate transaminase (AST), virological response and adverse reactions in the three groups were analyzed, respectivly.

Results

Total of 659 cases with HIV/AIDS were collected, among which, 167 cases were complicated with HCV infection, the complicated infection rate was 25.34%. The main HCV genotypes were type 3b (43 cases), type 3a (41 cases), type 1b (32 cases), type 6a (21 cases), undifferentiated subtype (25 cases), type 2a (5 cases); among which type 3 was the most, accounting for 50.29% (84/167). Among them, intravenous drug use accounted for 29.40% (142/483), sexual transmission accounted for 14.20% (23/162) and others accounted for 14.29% (2/14). Total of 125 patients had no obvious symptoms, and 42 patients had symptoms such as weakness, fever, night sweats, liver cirrhosis and lymphadenopathy. Liver function detection showed that 56 cases (56/167, 33.5%) were with normal liver function, 111 cases (111/167, 66.5%) with abnormal liver function, including 12 cases with cirrhosis in compensatory stage, 7 cases with degeneration of cirrhosis repayment period. The HIV/HCV coinfection rate dropped from 37.25% in 2008 to 15.00% in 2018, which showed a downward trend year by year (χ2 = 263.190, P < 0.001). The CD4+ T cell count of patients with HIV/HCV coinfection was significantly higher than that of patients with HIV/AIDS (t = 7.203, P < 0.001); but total bilirubin (TBil) (t = 29.101, P < 0.001), ALT (t = 25.382, P < 0.001), AST (t = 30.984, P < 0.001), HIV RNA (t = 9.190, P < 0.001) were significantly lower than those of patients with HIV/AIDS, all with significant differences. The amounts of CD4+ T lymphocytes in each group after treatment were higher than those before treatment, which was higher of patients in DAAs group than those of PegIFN group and IFN group; the levels of ALT and AST after treatment in three groups were lower than those before treatment, which higher of DAAs group was than those of in PegIFN group and IFN group, all with significant differences (CD4+ T: F = 4.252, P = 0.016; ALT: F = 125.400, P < 0.001; AST: F = 37.990, P < 0.001). The early virological response (EVR) rate (96.61%) of patients in DAAs group was significantly higher than that of PegIFN group (77.42%) and IFN group (71.74%); the end of treatment virological response (ETVR) rate (96.61%) of patients in DAAs group was significantly higher in PegIFN group (72.58%) and IFN group (63.04%). The sustained virological response (SVR) rate (94.92%) of DAAs group was significantly higher than those of PegIFN group (69.35%) and IFN group (67.39%), all with significant differences (EVR: χ2 = 13.011, P = 0.001; ETVR: χ2 = 19.227, P < 0.001; SVR: χ2 = 14.474, P < 0.001). The incidence of adverse reactions such as fatigue, fever, decreased white blood cells, decreased hemoglobin and decreased platelets of patients in DAAs group were significantly lower than those of PegIFN group and IFN group, with significant differences (fatigue: χ2 = 6.678, P = 0.035; fever: χ2 = 12.485, P = 0.002; decreased white blood cell: χ2 = 10.256, P = 0.006; decreased hemoglobin: χ2 = 13.962, P = 0.001; decreased platelet: χ2 = 11.681, P = 0.003).

Conclusions

The HIV/HCV coinfection rate was high, with HCV genotype 3 the most common, showing a year-on-year downward trend, and spreading mainly through intravenous drug use. DAAs for HIV/HCV co-infected patients were more conducive to the recovery of immune function and liver function, with a higher SVR rate and higher safety.

表1 659例HIV/AIDS感染者的基本资料
表2 167例完成抗HCV治疗患者的临床特征
表3 167例HIV/HCV共感染者的年份分布
表4 HIV/HCV共感染者与单纯HIV/AIDS感染者的实验室指标(± s
表5 HIV/HCV共感染者治疗前后CD4+ T细胞数、ALT和AST水平(± s
表6 HIV/HCV共感染者EVR、ETVR和SVR [例(%)]
表7 HIV/HCV共感染者不良反应发生率[例(%)]
[15]
Ghayomzadeh M, Etesami MS, Earnest CP,et al. Effect of a short-term lifestyle modification program on quality of life, anthropometric characteristics and CD4+ T cell count of HIV infected patients in Tehran/Iran: A randomized controlled trial[J]. Explore (NY),2019,15(4):308-315.
[16]
Mengist HM, Taye B, Tsegaye A. Intestinal parasitosis in relation to CD4+ T cells levels and anemia among HAART initiated and HAART naive pediatric HIV patients in a Model ART center in Addis Ababa, Ethiopia[J]. PLoS One,2015,10(2):e0117715.
[17]
陈家图,许铭清,张彩华, 等. 茂名地区HIV感染者合并TP HBV和HCV感染及对CD4+ T淋巴细胞的影响[J]. 中国艾滋病性病,2018,24(10):977-980.
[18]
刘娇,王川林,古雪, 等. HIV/AIDS患者与HBV, HCV共感染对外周血病毒载量及T淋巴细胞亚群表达影响的相关性分析[J]. 川北医学院学报,2018,33(2):184-187.
[19]
鲁春霞,郑澜,张军, 等. 注射吸毒者HCV单一感染和HIV/HCV共感染早期促进T细胞免疫衰老的研究[J]. 中国药物依赖性杂志,2017,26(3):182-188, 194.
[20]
古善群,李重熙,白劲松, 等. DAAs治疗HIV/HCV共感染患者HCV的疗效分析[J]. 昆明医科大学学报,2018,39(5):120-123.
[21]
张熙,李永国. 慢性丙型肝炎直接抗病毒药物应用现状及存在问题[J]. 临床肝胆病杂志,2018,34(4):853-857.
[22]
游国琼,王丽,段萌, 等. 直接抗病毒药物治疗HCV相关肝硬化的效果及安全性[J]. 临床肝胆病杂志,2019,35(1):187-190.
[23]
Shafran Stephen D. HIV coinfected have similar SVR rates as HCV monoinfected with DAAs: It’s time to end segregation and integrate HIV patients into HCV trials.[J]. Clin Infect Dis,2015,61(7):1127-1134.
[24]
Lazarus JV, Pericàs JM, Picchio C, et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade[J]. J Intern Med,2019,286(5):503-525.
[25]
中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志,2019,35(12):2670-2686.
[1]
Shenge Juliet A, Odaibo Georgina N, Olaleye David O. Correction: phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria[J]. PLoS One,2019,14(11):e0225679.
[2]
培尔顿·米吉提,张跃新,买买提力·吾布力, 等. 2005-2011年新疆地区HIV/AIDS病人中HCV感染状况及影响因素分析[J]. 中国艾滋病性病,2015,21(6):477-480.
[3]
彭君,徐联芳,张永喜, 等. 艾滋病ICD-10常见编码错误案例分析[J]. 中国病案,2016,17(10):27-34.
[4]
陈新谦,金有豫,汤光主编. 陈新谦新编药物学[M]. 18版. 北京: 人民卫生出版社,2019,7:2.
[5]
中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2015年版)[J/CD]. 中国肝脏病杂志(电子版),2015,7(3):19-35
[6]
Zuckerman AD, Douglas A, Whelchel K, et al. Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?[J]. PLoS One,2019,14(11):e0225434.
[7]
Shenge JA, Odaibo GN, Olaleye DO. Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria[J]. PLoS One,2019,14(2):e0210724.
[8]
邓浩辉,李晓强,高洪波, 等. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析[J]. 实用肝脏病杂志,2019,22(5):656-659.
[9]
李重熙,刘俊,白劲松, 等. 昆明地区2010年-2016年HIV/HCV共感染流行特征[J]. 昆明医科大学学报,2018,39(12):103-107.
[10]
韩婷婷,张建波,申元英. 大理市992例HIV/AIDS患者合并HBV, HCV感染情况调查[J]. 大理大学学报,2019,4(8):93-96.
[11]
陈昭云,孙燕,马淑焕, 等. 河南部分地区HIV/AIDS病人合并HCV感染状况调查分析[J]. 中国艾滋病性病,2018,24(4):334-336.
[12]
Shumway M, Luetkemeyer AF, Peters MG, et al. Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences.[J]. AIDS Care,2019,31(11):1340-1347.
[13]
Alkindi S, Al-Umairi N, Jaju S,et al. Prevalence of hepatitis B, hepatitis C, and HIV in multiply transfused sickle cell disease patients from Oman[J]. Mediterranean J hematology I,2019,11(1):e2019058.
[14]
George NI, Lauren AB, Pamela KG,et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores[J]. Gastroenterology,2019,157(5):1264-1278. e4.
[1] 张焱, 刘春媚, 姚瑾, 陈苗苗, 徐雯, 黄品同. 超声O-RADS分类和临床特征对不同病理类型卵巢浆液性肿瘤的诊断价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(03): 268-274.
[2] 顾盼盼, 董传莉, 宋梦瑶, 瞿色华, 杨小迪, 周瑞. 不完全性川崎病患儿临床特征及冠状动脉损害情况分析[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(04): 446-451.
[3] 丁科, 张亚琼, 刘杰, 邓莉平, 张永喜, 熊勇. 获得性免疫缺陷综合征相关淋巴瘤患者的临床特征及生存状况的变化趋势[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 278-284.
[4] 张超, 张珍, 马梁, 穆欢欢, 刘彩玲. 腹腔镜胰十二指肠切除术术后C级胰瘘患者临床特征及影响因素研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 675-678.
[5] 颜晓敏, 崔嵘嵘. 23例乳腺佩吉特病的经验交流[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(03): 353-354.
[6] 高佳, 姜吉询, 王鑫, 吴婷, 向江明. 病理性乳头溢液单中心临床分析附168例报告[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(03): 323-326.
[7] 杨柳, 陈佳, 孙雅娟, 陈娇, 谭明超, 龚明福. 抗中性粒细胞胞浆抗体相关性血管炎的胸部CT 及临床特征分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 744-749.
[8] 杨攀, 黄晓寒, 邓才霞, 周利航, 周向东, 罗虎. SMARCA4缺失的胸部未分化肿瘤临床特征及预后分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 529-534.
[9] 何俊, 易淑华, 陈婷婷, 杨玉, 李红雨, 谢飞, 何健. 妊娠并发社区获得性肺炎临床特征及降钙素原和炎症指数对其诊断意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(03): 421-425.
[10] 李苑莹, 龚金如, 陈晓璇, 孙瑞琳. 成人肺炎支原体肺炎临床特征分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 223-228.
[11] 李广林, 唐凯, 卢秀珍. 部分调节性内斜视的临床研究进展[J/OL]. 中华眼科医学杂志(电子版), 2024, 14(03): 177-181.
[12] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[13] 刘昌恩, 李岩, 张其德. 基于内镜筛查发现的自身免疫性胃炎的临床特征分析[J/OL]. 中华胃肠内镜电子杂志, 2024, 11(04): 233-237.
[14] 王宇, 张泽锴, 吴明胜, 王高祥, 孙效辉, 王君, 徐美青, 李田, 徐世斌, 解明然. 术后病理诊断为良性肺结节323例患者临床特征分析[J/OL]. 中华胸部外科电子杂志, 2024, 11(03): 167-174.
[15] 赵方, 邓宇傲, 饶嫚, 刘瑜, 邓秋霞, 张秋月, 张海涛, 宋莹, 王思苑, 贾新云, 刘映霞. HIV/TB 双重感染者发生免疫重建炎性综合征时血清锌及相关炎症因子的变化特征[J/OL]. 中华卫生应急电子杂志, 2024, 10(04): 213-217.
阅读次数
全文


摘要